Patent intelligence · US
US 8987305
2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
Patent details — US 8987305
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 24, 2015
- Expiration
- Mar 19, 2035
- Applicant
- APTOSE BIOSCIENCES INC.
- Claims
- 57
- CPC classes
- A61K, A61K31/4164, A61K31/4178, A61K31/4184
Quick answer
US 8987305 (2,4,5-trisubstituted imidazoles and their use as anti-microbial agents) is held by APTOSE BIOSCIENCES INC.. Status: granted. Granted Mar 24, 2015. Expires Mar 19, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- APTOSE BIOSCIENCES INC.
- Grant date
- Expiration
- Claims
- 57
- CPC classes
- A61K, A61K31/4164, A61K31/4178, A61K31/4184, A61K31/4188, A61K31/4375
More from APTOSE BIOSCIENCES INC.
Related pharmaceutical patents in our USPTO index.
-
US 11279703
Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
granted -
US 11149047
Aryl imidazoles for treatment of cancer
granted -
US 11104957
Compositions and methods for treating cancers
granted -
US 10080739
Aryl imidazoles and their use as anti-cancer agents
granted -
US 9567643
Compositions and methods for treating cancers
granted -
US 8969372
Aryl imidazoles and their use as anti-cancer agents
granted
Frequently asked questions
What is US patent 8987305?
US 8987305 (2,4,5-trisubstituted imidazoles and their use as anti-microbial agents) is held by APTOSE BIOSCIENCES INC.. Status: granted. Granted Mar 24, 2015. Expires Mar 19, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8987305?
APTOSE BIOSCIENCES INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 8987305 expire?
Our index shows an expiration date of Mar 19, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.